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See Article, pages 34–40Hepatitis E virus (HEV) is an enterically transmitted virus of 27–
34 nm diameter whose genome consists of a poly-adenylated sin-
gle stranded RNA of 7.2 kb length with 30 and 50 non-coding end
and three partially overlapping open reading frames (ORFs) [1].
While ORF1 codes for non-structural proteins necessary for its
replication, ORF2 and ORF3 code for the viral capsid protein [1].
The genome of HEV has been cloned, sequenced, its structural
regions have been expressed in vitro, and both serological diagno-
sis and detection of HEV-RNA in sera, stool, and bile have been
established by RT-PCR [1,2].
Due to its enteric route of transmission, it is the most common
cause of both acute icteric and anicteric hepatitis in areas with
poor sanitation and is known as hepatitis E [1]. Multiple epidem-
ics of hepatitis E involving thousands of people have been
reported from developing countries like India, China, Southeast
and Central Asia, Northern and Western Africa [2]. The source
of HEV in most of these outbreaks has been traced to contami-
nated drinking water [2]. The virus has been identiﬁed, in the fae-
ces of volunteers who ingested faeces of patient having acute
hepatitis E, using immune electron microscopy, thereby conﬁrm-
ing its faeco-oral enteric route of transmission [3,4]. However,
transmission through contaminated food, transmission through
infected blood products, and maternal-foetal transmission of
HEV have been reported from hyper-endemic regions like the
Indian subcontinent [1]. Therefore, HEV remains the most fre-
quent cause of acute hepatitis, acute liver failure, and acute-on-
chronic liver failure in hyper-endemic regions and represents
an important public health problem [5,6].
Reports from hyper-endemic regions like South Asia have
conﬁrmed that pregnant women and patients with chronic liver
disease are at an increased risk to contract HEV and subsequently
develop severe liver disease leading to liver failure and high
mortality rate of around 60–70% [1,5,6]. However, acute hepatitis
E in previously healthy individuals is usually self limiting and
resolves within 4 to 6 weeks and case fatality rates in most
epidemics have been reported to vary between 0.5% to 4% [1,2].
Chronic sequelae among patients during epidemic and sporadic
setup have not been documented [7].Journal of Hepatology 20
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(S.K. Acharya).In non-endemic regions (Developed Industrialized Nations),
where safe water supply has been ascertained, epidemic out-
breaks have never been documented and hepatitis E associated
deaths have not been recorded in immune competent healthy
populations. A few years back, sporadic acute hepatitis E cases
from these regions were predominantly documented among
exposed travellers returning from HEV hyper-endemic regions.
However, in recent years, a small series of cases related to
autochthonous transmission of hepatitis E are being reported
from developed nations like USA, Europe, Japan, Taiwan, Austra-
lia, and Hong Kong [2]. In the present issue of the journal, a long
term prospective study from Italy, conducted over 15 years, eval-
uated the magnitude of acute hepatitis E among patients with
acute non A, non C hepatitis (n = 651). This study revealed that
about one ﬁfth (n = 134, 20.6%) of tested patients had acute
HEV infection, which was diagnosed by the detection of IgM
anti-HEV and/or HEV-RNA in their sera [8]. Among these 134
patients with acute hepatitis E, 81.3% (n = 109) developed the dis-
ease within 1 to 4 weeks after returning to Italy subsequent to
travelling to the Indian subcontinent, Morocco, and other coun-
tries that are hyper-endemic for HEV. Three patients (2.3%) were
considered to have acquired HEV infection through infra-familial
transmission. The remaining 22 (16.4%) were diagnosed as
autochthonous acute hepatitis E, because they either (1) did not
travel abroad, (2) denied contact with acute hepatitis E patients
or people from abroad, (3) were not drug addicts or had transfu-
sion, (4) did not eat raw undercooked shellﬁsh and did not have
occupational risks like swine handlers/pig farmers. A proportion
of viral isolates (n = 39), from patients of acute hepatitis E who
travelled to hyper-endemic area, and autochthonous group
(n = 5), were further analysed for genotyping of the virus using
PCR products of ORF2 region which revealed that all isolates of
the former group had genotype 1 HEV infection whereas all iso-
lates of autochthonous HEV belonged to genotype 3 [8].
HEV is placed in the Hepevirus genus and is the only member
of this family. In 1997, Meng et al. [9] ﬁrst identiﬁed, from swine
in Midwestern USA, HEV strains that shared with the Burmese
and Mexican (hyper-endemic for HEV) isolates of human HEV
[10], 90–92% and 79–83% identity at the amino acid level in the
ORF2 and ORF3 regions, respectively. Presence of HEV RNA in fae-
ces and anti-HEV antibodies in sera of domestic swine, cattle,
donkeys, deer, mules, and other animals had been reported ear-
lier [11].11 vol. 54 j 9–11
Table 1
Hepatitis E virus: Genotypes, geographical prevalence, viral and disease characteristics.
Genotype Reservoir Animal to 
human
transmission 
Water borne
transmission 
Geographical
distribution
Severity Chronicity Relation to 
pregnancy
Causes 
ACLF
Epidemics
1 Human No Yes South Asia, Central 
Asia, China,
 Sub-Saharan Africa 
Yes No Cause 
severe 
disease
Yes Yes 
2 Human No Yes Mexico, Nigeria Yes No NK NK Yes 
3 Swine Yes NK Industrialized countries, 
USA, Europe, Japan 
No Yes NK NK No 
4 Swine Yes Yes Taiwan, Japan, China No NK NK NK No 
NK, Not Known.
EditorialHowever, initial reports from the USA, on acute hepatitis E
[10,12,13] in human and HEV isolates from patients showing
nucleotide and amino acid heterogeneity similar to human iso-
lates of Burmese and Mexican strains, prompted further investi-
gation and the search for sources of HEV reservoirs in
industrialized countries. HEV has mainly been found in pigs from
all parts of the world, irrespective of HEV endemicity and the fre-
quency of acute hepatitis E in respective human populations
[1,2]. It has also been found that swine HEV naturally infects pigs,
causing viremia and an antibody response that cross-reacts with
human strains [2]. Furthermore, zoonotic human HEV infection,
particularly in industrialized and developed nations, was ﬁrst
suspected after the detection of closely similar HEV isolates in
two autochthonous cases in regions of the USA with locally pre-
valent swine HEV isolates [10,12,13]. The zoonotic transmission
of HEV was then conﬁrmed by a Japanese case series of acute
hepatitis E where patients consumed inadequately cooked deer
meat a few weeks before the illness declared itself, and HEV iso-
lated from these patients were akin to the HEV isolates detected
from the frozen left over deer meat [14]. Various additional evi-
dences have supported the existence of zoonotic transmission
in non-endemic region [15].
By now, multiple reports on the presence of autochthonous
acute hepatitis E in non-endemic, industrialized countries like
USA, France, Spain, Italy, Greece, Netherlands, UK and non-ende-
mic developed Asian-Paciﬁc countries like Australia, Japan and
Taiwan have appeared in the English literature [2], and isolates
from these patients with acute hepatitis E have been analysed
and genotyped [2]. Despite the lack of consensus regarding the
genotyping process, genotyping of HEV isolates is presently per-
formed based on the ORF2 region and genotypes are deﬁned as
viruses having a nucleotide divergence of not more than 20% [16].
Based on genome sequence analysis, human and swine HEV
isolates have been categorized into four distinct genotypes 1–4
(Table 1). Each genotype has several subtypes but all genotypes
have common serotypes [1,2,15]. As indicated earlier, it is clear
that acute autochthonous hepatitis E is being reported with
increasing frequency in developed and industrialized country,
thus conﬁrming HEV as a cause of acute hepatitis all over the
world. However, while genotype 1 and 2 are prevalent in
hyper-endemic regions where the reservoir for HEV seems to
be human (continuous subclinical infection [17]), genotype 3
and 4 are prevalent in USA, Europe, and Japan where the reservoir
seems to be represented by pigs, and the zoonotic transmission is
considered to be the cause of infection of human beings, leading10 Journal of Hepatology 2to autochthonous acute HEV. Genotype 4 has been identiﬁed in
both swine and human patients with acute hepatitis E in China,
Taiwan and Japan, but in the Indian subcontinent, even though
swine HEV belongs to genotype 4, all human cases to date had
genotype 1 infection [2]. All swine isolates belong to genotype
3 and 4 and no animal isolates to date belong to genotype 1
and 2. This may indicate that genotype 1 and 2 may not be capa-
ble of crossing the species barrier whereas genotype 3 and 4 can
do so. On the other hand, genotype 1 and 2 cause severe liver dis-
ease whereas genotype 3 and 4 cause milder disease [1,2]. It is
further evident by the observation that the seroprevalence of
anti-HEV in populations belonging to developed nations varies
from 5–21% [18], indicating frequent exposure but epidemic out-
breaks and the low frequency of autochthonous hepatitis would
suggest that these viruses may be more benign than those preva-
lent in hyper-endemic region. Despite increasing reports on the
occurrence of autochthonous acute hepatitis E in industrialized
nations, acute liver failure and acute-on-chronic liver failure,
due to autochthonous acute hepatitis E belonging to genotype 3
and 4, have not yet been documented.
In the paper reported in this issue [8], 96 (71.6%) patients
with acute hepatitis E were viremic, as shown by the presence
of HEV RNA. Even though the paper did not provide the exact
frequency of viremia among autochthonous cases, many of them
would presumably be viremic. It may be relevant to these popu-
lations where autoimmune hepatitis (AIH) is more prevalent and
corticosteroid therapy is the mainstay of treatment. AIH in these
parts of the world is frequently diagnosed by excluding known
causes of viral hepatitis, and autoimmune markers may be
absent in about 30–40% of such cases. Therefore, it seems that
a serological test for HEV may be relevant for such patients,
before embarking upon an immunosuppressive therapy. With
the increasing prevalence of non-alcoholic fatty liver disease
and alcoholic liver disease, HEV super-infection might be a cause
of deterioration in patients who have never been investigated.
HEV super-infection in such patients has already been docu-
mented to cause rapid decompensation [5,6]. However, these
reports have emanated from the Indian subcontinent which is
hyper-endemic for HEV where human disease is caused by
HEV genotype 1 [2]. Whether HEV genotype 3 and 4 super-infec-
tion would cause such sequel is unclear and needs prospective
evaluation. A prototype example is a recent report on drug
induced hepatitis (DH) in the UK [19]. In this report, in 13% of
patients DH was due to acute hepatitis E, as diagnosed by a later
analysis of their stored sera.011 vol. 54 j 9–11
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Data on HEV in the developed world is inadequate because of
the belief that HEV prevalence and transmission is extremely
infrequent in these areas. The seroprevalence studies from these
countries had used ELISA assays, to detect IgG anti-HEV antibody,
manufactured by either GeneLabs (Singapore) or/and Abbott,
(Germany) which uses truncated recombinant peptides of ORF2
and ORF3 regions from the Burmese and Mexican prototype
sequences [20]. A recent study showed that the above mentioned
ELISA assays may be less sensitive to detect IgG anti-HEV anti-
body in the sera [21]. A recently developed, more sensitive ELISA
(IgG EIA kit, Wantai, Beijing, China) with a lower limit of detec-
tion for IgG anti-HEV (0.25 WHO unit/ml) was compared with
the frequently used GeneLab IgG anti-HEV kit that has a higher
limit of detection for IgG anti-HEV (2.5 WHO unit/ml) [21]. Both
these assays were used for the analysis of stored sera of known
acute hepatitis E and donor blood from the UK. The Wantai kit
was positive in more sera of proven cases as compared to the
GeneLab kit (98% vs 56%) and resulted in a markedly higher
estimate of seroprevalence in blood donors (16.2% vs 3.6%).
Therefore, the actual seroprevalence might have been underesti-
mated in most of the industrialized countries due to the use of
less sensitive assays. Furthermore, IgM anti-HEV antibody in
autochthonous acute hepatitis E may not be detectable by less
sensitive assays and diagnosis has been ascertained by detection
of HEV-RNA in the sera or stool [22]. It may be relevant to reas-
sess the sero-epidemiology of HEV in the developed nations, and
identify the other sources of HEV transmission in view of the
increasing number of reports on acute hepatitis E, as documented
by the paper in this issue of the journal. In addition to zoonotic
transmission, contaminated water, as a source of acute hepatitis
E, has been reported from France [23]. During a 13 month dura-
tion, the evaluation of consecutive patients with acute hepatitis
in South Hampshire, UK, revealed that acute hepatitis E was more
frequent than acute hepatitis A and B and none of the patients
had a history of travel abroad or had consumed any raw meat
in the recent past, raising the suspicion of transmission through
contaminated water or food [24].
It is evident that HEV is endemic in most part of the developed
and industrialized nations indicating its global prevalence. While
HEV genotype 1 is hyper-endemic in Asia and Africa, where it
causes outbreaks, sporadic acute hepatitis, acute liver failure,
and acute-on chronic liver failure; HEV genotype 3 and 4 are pre-
valent in the industrialized and developed nations and increasing
reports on autochothonous acute hepatitis E due to these viruses
are being identiﬁed. The reservoir for genotype 1 has been iden-
tiﬁed to be human whereas the reservoir for the genotype 3 and 4
seems to be pigs, and therefore zoonotic transmission is more
prevalent in these regions. However, the latter viruses have not
been implicated in causing severe liver disease and more studies
are needed to further clarify this observation. (Table 1). Genotype
2 like genotype 1 has been reported from Mexico and Nigeria
with similar epidemiological and sporadic features. Due to the
global prevalence of HEV, an effective vaccine with long lasting
immunity is urgently needed to protect people throughout the
world and therefore it is time that HEV associated diseases are
not considered as a disease of the developing world where sani-
tation is inadequate. HEV, indeed, is prevalent globally and is of
public health importance, which requires the attention of public
health experts, academia, and the health authorities throughout
the world in order to reduce the morbidity and mortality caused
by it.Journal of Hepatology 2Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.References
[1] Acharya SK, Panda SK. Hepatitis E Virus: epidemiology, diagnosis, pathology
and prevention. Trop Gastroenterol 2006;27:63–68.
[2] Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroen-
terol Hepatol 2009;24:1484–1493.
[3] Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in
non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology
1983;20:23–31.
[4] Chauhan A, Jameel S, Dilawari JB, Chawla YK, Kaur U, Ganguly NK. Hepatitis E
virus transmission to a volunteer. Lancet 1993;341:149–150.
[5] Acharya SK, Sharma PK, Singh R, Mohanty SK, Madan K, Jha JK, et al. Hepatitis
E virus (HEV) infection in patients with cirrhosis is associated with rapid
decompensation and death. J Hepatol 2007;46:387–394.
[6] Bhatia V, Singhal A, Panda SK, Acharya SK. A 20-year single center experience
with acute liver failure during pregnancy: Is the prognosis really worse?
Hepatology 2008;48:1577–1585.
[7] Panda SK, Acharya SK. Hepatitis E virus infection: Where are we? Natl Med J
India 1998;11:56–58.
[8] Romano L, Paladini S, Tagliacarne C, Canuti M, Bianchi S, Zanetti AR.
Hepatitis E in Italy: A long-term prospective study 2010.
[9] Meng XJ, Purcell RH, Halbur PG, et al. A novel virus in swine is closely
related to the human hepatitis E virus. Proc Natl Acad Sci USA 1997;94:
9860–9865.
[10] Schlauder GG, Dawson GJ, Erker JC, et al. The sequence and phylogenetic
analysis of novel hepatitis E virus isolated from patient with acute hepatitis
reported in the United States. J Gen Virol 1998;79:447–456.
[11] Clayson ET, Innis BL, Myint KS, Narupiti S, Vaughn DW, Giri S, et al. Detection
of hepatitis E virus infections among domestic swine in the Kathmandu
Valley of Nepal. Am J Trop Med Hyg 1995:53225–53232.
[12] Kwo PY, Schlauder GG, Carpenter HA, et al. Acute hepatitis E by a new isolate
acquired in the United States. Mayo Clin Proc 1997;72:1133–1136.
[13] Erker JC, Desai SM, Schlauder GG, Dwason GJ, Mushahwar IK. A
hepatitis E virus variant from the United States: molecular character-
ization and transmission in cynomolgus macaques. J Gen Virol 1999;
80:681–690.
[14] Matsuda H, Okada K, Takahashi K, Mishiro S. Severe hepatitis E virus
infection after ingestion of uncooked liver from a wild boar. J Infect Dis
2003;188:944.
[15] Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in
developed countries. Lancet Infect Dis 2008;8:698–709.
[16] van der Poel HC, van der Poel WH, Brandstatter G. Hepatitis E: an overview.
Microbes Infect 2002;4:657–666.
[17] Aggarwal R. Hepatitis E: Is it a blood-borne pathogen? J Gastroenterol
Hepatol 2004;19:729–731.
[18] Teshale EH, Hu DJ, Holmberg SD. The two faces of hepatitis E virus. Clin
Infect Dis 2010;51:328–334.
[19] Dalton HR, FFellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow
U, et al. The role of hepatitis E virus testing in drug induced liver injury.
Aliment Pharmacol Ther 2007;26:1429–1435.
[20] Ghabrah TM, Tsarev S, Yarbough PO, Emerson SU, Strickland GT, Purcell RH.
Comparison of tests for antibody to hepatitis E virus. J Med Virol
1998;55:134–137.
[21] Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two
commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV
IgG seroprevalence data in developed countries. J Med Virol 2010;82:
799–805.
[22] Moucari R, Bernuau J, Nicand E, Cazals-hatem D, Valla D, Marcellin P, et al.
Acute hepatitis E with severe jaundice: report of three cases. Eur J
Gastroenterol Hepatol 2007;19:1012–1015.
[23] Renou C, Moreau X, Pariente A, Cadranel JF, Maringe E, Morin T, et al. A
national survey of acute hepatitis E in France. Aliment Pharmacol Ther
2008;27:1086–1093.
[24] De Silva AN, Muddu AK, Iredale JP, Sheron N, Khakoo SI, Pelosi E.
Unexpectedly high incidence of indigenous acute hepatitis E within South
Hampshire: time for routine testing? J Med Virol 2008;80:283–288.011 vol. 54 j 9–11 11
